茵栀黄口服液联合清蛋白治疗新生儿病理性黄疸疗效及安全性研究

发布时间：2018-07-26 09:08

【摘要】：目的探讨茵栀黄口服液联合清蛋白治疗新生儿病理性黄疸疗效、安全性及可能机制。方法收集150例新生儿病理性黄疸患儿,分为对照组75例和观察组75例。常规治疗基础上,对照组给予清蛋白,而观察组则联合给予茵栀黄口服液治疗。比较对照组和观察组患儿临床疗效、血清胆红素水平、胆红素下降速度、血清超敏C反应蛋白(hs-CRP)、甲胎蛋白(AFP)、转铁蛋白(TRF)水平及不良反应发生情况。结果疗效评价显示,观察组患儿治疗总有效率明显高于对照组(96.0%vs.86.7%,P0.05)。治疗后,与对照组相比,观察组患儿血清胆红素水平显著降低(110.2±17.1)μmol/L vs.(148.8±19.1)μmol/L,胆红素日均下降程度更明显[(45.1±4.5)μmol·L-1·d-1 vs.(28.3±5.2)μmol·L-1·d-1],退黄时间明显缩短[(5.1±1.8)d vs.(7.6±1.6)d],血清hs-CRP、AFP水平明显降低[(7.3±1.6)mg/L vs.(13.7±2.2)mg/L,(13.2±2.1)mg/L vs.(18.1±2.5)mg/L],TRF水平明显升高(1.97±0.28)g/L vs.(1.64±0.24)g/L,组间比较差异均有统计学意义(均P0.05)。治疗期间,两组患儿均未出现严重不良反应病例,观察组不良反应发生率明显低于对照组(8.0%vs.20.0%,P0.05)。结论茵栀黄口服液联合清蛋白治疗新生儿病理性黄疸疗效可靠,能够显著提高临床疗效,临床上值得进一步研究。
[Abstract]:Objective to investigate the efficacy, safety and possible mechanism of Yinzhihuang oral liquid combined with albumin in the treatment of neonatal pathological jaundice. Methods 150 neonates with pathological jaundice were divided into control group (75 cases) and observation group (75 cases). On the basis of routine treatment, the control group was given albumin, while the observation group was treated with Yinzhihuang oral liquid. The clinical efficacy, serum bilirubin level, decreasing rate of bilirubin, serum hypersensitive C-reactive protein (hs-CRP), alpha-fetoprotein (AFP), transferrin (TRF) and adverse reactions were compared between the control group and the observation group. Results the total effective rate of the observation group was significantly higher than that of the control group (96.0vs.86.7p0.05). After treatment, compared with the control group, 瑙傚療缁勬偅鍎胯��娓呰儐绾㈢礌姘村钩鏄捐憲闄嶄綆(110.2卤17.1)渭mol/L vs.(148.8卤19.1)渭mol/L,鑳嗙孩绱犳棩鍧囦笅闄嶇▼搴︽洿鏄庢樉[(45.1卤4.5)渭mol路L-1路d-1 vs.(28.3卤5.2)渭mol路L-1路d-1],閫，

本文编号：2145531